Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 33, Issue 7, 2004, Pages 721-728

  Porta, C ^a   Caporali, R ^a   Epis, O ^a   Ramaioli, I ^a   Invernizzi, R ^a   Rovati, B ^a   Comolli, G ^a   Danova, M ^a   Montecucco, C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autografting; CD34; Hematopoiesis; Mobilization; RA

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBODY TITER; APOPTOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD LEVEL; BONE MARROW; BONE MARROW CELL; BONE MARROW CULTURE; BURST FORMING UNIT E; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENIC ASSAY; COLONY FORMING UNIT GM; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MORPHOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; TREATMENT INDICATION;

ADULT; AGED; ANTIGENS, CD34; ARTHRITIS, RHEUMATOID; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL DIVISION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; MYELOID CELLS; PATIENT SELECTION; TRANSPLANTATION, AUTOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4444245363     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704407     Document Type: Article

References (54)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269-281.
2. Pineus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol 2001; 15: 139-170.
3. Mitchell DM, Spitz PW, Young DY et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-714.
4. Markenson JA. World wide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthr Rheum 1991; 21 (Suppl. 1): 4-12.
5. Ikehara S, Good RA, Nakamura T et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 1985; 82: 2483-2487.
6. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995; 16: 1-6.
7. Burt RK, Traynor AE, Ramsey-Goldman R. Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med 1997; 337: 1777 (letter).
8. Tyndall A, Grathwohl A. Blood and marrow stem cell transplant in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997; 36: 390-392.
9. Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
10. van Bekkum DW. Autologous stem cell transplantation for treatment of autoimmune diseases. Stem Cells 1999; 17: 172-178.
11. Tyndall A, Fassas A, Passweg J et al. Autologous haematopoietic stem cell transplants for autoimmune disease. Feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Diseases. Bone Marrow Transplant 1999; 24: 729-734.
12. Burt RK, Marmont A, Schroeder J et al. Intense immune suppression for systemic lupus - the role of hematopoietic stem cells. J Clin Immunol 2000; 20: 31-37.
13. Traynor AE, Schroeder J, Rosa RM et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation. Lancet 2000; 356: 701-707.
14. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
15. Verburg RJ, Toes RE, Fibbe WE et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis: a review. Hum Immunol 2002; 63: 627-637.
16. Tyndall A, Koike T. High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future directions. Intern Med 2002; 41: 608-612.
17. Snowden J, Moore J, Passweg J et al. Autologous hemopoietic stem cell transplantation (HSCT) in rheumatoid arthritis (RA): a report from the EBMT and IBMTR. Bone Marrow Transplant 2002; 29 (Suppl. 2): S14 (abstract O126).
18. Katevas P, Andonopoulos AP, Kourakli-Symeonidis A et al. Peripheral blood mononuclear cells from patients with rheumatoid arthritis suppress erythropoiesis in vitro via the production of tumor necrosis factor alpha. Eur J Haematol 1994; 53: 26-30.
19. Gembitskii EV, Mazurov VI, Lila AM et al. Changes in functional activity of granulocytopoiesis in patients with rheumatoid arthritis. Klin Med 1991; 69: 51-54.
20. Ali M, Ponchel F, Wilson KE et al. Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. J Clin Invest 2001; 107: 519-528.
21. Barron KS, DeCunto CL, Montalvo JF et al. Abnormalities of immunoregulation in juvenile rheumatoid arthritis. J Rheumatol 1989; 16: 940-948.
22. Iglesias A, Deulofeut H, Dubey DP et al. Functional deficiency of antigen-presenting cells in the synovial fluid of rheumatoid arthritis. Hum Immunol 1992; 35: 109-115.
23. Papadaki HA, Marsh JC, Eliopoulos GD. Bone marrow stem cells and stromal cells in autoimmune cytopenias. Leuk Lymphoma 2002; 43: 753-760.
24. Otsuka T, Okamura S, Harada M et al. Multipotent hemopoietic progenitor cells in patients with systemic lupus erythematosus. J Rheumatol 1988; 15: 1085-1090.
25. Ikehara S. Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment. J Mol Med 1998; 1: 5-16.
26. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
27. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24: 91-104.
28. Riccardi A, Danova M, Paccagnella A et al. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor. Ann Haematol 1993; 66: 185-193.
29. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1993; 77: 400-409.
30. + hematopoietic cells following chemotherapy plus colony-stimulating factor in advanced breast cancer. Int J Cancer 1995; 63: 646-651.
31. Danova M, Riccardi A, Ucci G et al. Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study. Br J Cancer 1990; 62: 781-785.
32. Carlo Stella C, Cazzola M, Ganser A et al. Synergistic antiproliferative effect of recombinant interferon-γ with recombinant interferon-γ on chronic myelogenous leukemia haematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, CFU-GM). Blood 1988; 72: 1293-1299.
33. Means Jr RT, Krantz SB. Inhibition of human erythroid colony-forming units by gamma-interferon can be corrected by recombinant human erythropoietin. Blood 1991; 78: 2564-2567.
34. Means Jr RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639-1647.
35. Collins DP. Cytokine and cytokine receptor expression as a biological indicator of immune activation: important considerations in the development of in vitro model systems. J Immunol Met 2000; 243: 125-145.
36. Negoescu A, Lorimier P, Labat-Moleur B et al. In situ apoptotic cell labelling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 1996; 44: 959-968.
37. Berthelot JM, Bataille R, Maugars Y, Prost A. Rheumatoid arthritis as a bone marrow disorder. Semin Arthritis Rheum 1996; 26: 505-514.
38. Cline MJ, Golde DW. Immune suppression of hematopoiesis. Am J Med 1978; 64: 301-310.
39. Hamilton JA. Rheumatoid arthritis: opposing actions of hematopoietic growth factors and slow-acting antirheumatic drugs. Lancet 1993; 342: 536-539.
40. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
41. + cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997; 89: 1189-1196.
42. Ferrari S, Danova M, Porta C et al. Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients. Int J Oncol 1999; 15: 811-815.
43. 0. Blood 2000; 96: 4185-4193.
44. De Boer F, Drager AM, Pinedo HM et al. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002; 29: 249-255.
45. Philpott NJ, Prue RL, Marsh JC et al. G-CSF mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: role of G-CSF as survival factor. Br J Haematol 1997; 97: 146-152.
46. Theilgaard-Mönch K, Raaschou-Jensen K, Palm H et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant 2001; 28: 1073-1082.
47. + hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica 1999; 84: 517-524.
48. Papadaki HA, Kritikos HD, Gemetsi C et al. Bone marrow progenitor cell reserve and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002; 99: 1610-1619.
49. Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 2002; 31: 251-259.
50. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-368.
51. + cells of patients with aplastic anemia. Br J Haematol 1995; 91: 245-252.
52. Snowden JA, Nink V, Cooley M et al. Composition and function of peripheral blood stem and progenitor cell harvests from patients with severe active rheumatoid arthritis. Br J Haematol 1998; 103: 601-609.
53. Moore J, Brooks P, Milliken S et al. A pilot randomized trial comparing CD34-selected vs unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301-2309.
54. Caporali R, Perotti C, Pedrazzoli P et al. Cyclophosphamide plus granulocyte colony stimulating factor (G-CSF) is more effective than G-CSF alone in mobilizing hemopoietic progenitor cells in severe, refractory rheumatoid arthritis. Haematologica 2001; 86: 106-107 (letter).